Ceritinib
FDA-approved product (capsule, oral), marketed as Zykadia.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Neoplasm
- Non-small cell lung carcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Anaplastic lymphoma kinase (alk) inhibitors
- FDA pharmacologic class
- Kinase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ceritinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
NCT01685060 · start 2012-11-26
Registered record
- Registry ID
- NCT01685060
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- LDK378
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-11-26
- Completion
- 2016-03-29
- Enrolment
- 140
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-Small Cell Lung CancerInterventionLDK378PhasePhase 2Registry statusCompletedStudy of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
NCT01634763 · start 2012-06
Registered record
- Registry ID
- NCT01634763
- Conditions
- Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
- Interventions
- LDK378
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-06
- Completion
- 2016-01
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)InterventionLDK378PhasePhase 1Registry statusCompletedA Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
NCT01283516 · start 2011-01-24
Registered record
- Registry ID
- NCT01283516
- Conditions
- Tumors Characterized by Genetic Abnormalities of ALK
- Interventions
- LDK378
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-01-24
- Completion
- 2016-05-03
- Enrolment
- 304
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTumors Characterized by Genetic Abnormalities of ALKInterventionLDK378PhasePhase 1Registry statusCompletedExpanded Treatment Protocol With LDK378 in ALK(+) NSCLC
NCT01947608
Registered record
- Registry ID
- NCT01947608
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- LDK378
- Study type
- EXPANDED_ACCESS
- Phase
- Not recorded
- Registry status
- No longer available
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-small Cell Lung Cancer (NSCLC)InterventionLDK378PhaseNot recordedRegistry statusNo longer availableManaged Access Programs for LDK378, Ceritinib
NCT05100134
Registered record
- Registry ID
- NCT05100134
- Conditions
- Anaplastic Lymphoma Kinase (ALK)- Positive Tumors; Non-small Cell Lung Cancer (NSCLC)
- Interventions
- ceritinib
- Study type
- EXPANDED_ACCESS
- Phase
- Not recorded
- Registry status
- No longer available
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnaplastic Lymphoma Kinase (ALK)- Positive Tumors; Non-small Cell Lung Cancer (NSCLC)InterventionceritinibPhaseNot recordedRegistry statusNo longer available